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Background: Hypertension is one of the recognized risk factors of cardiovascular diseases 
in adult diabetic patients. High prevalence of suboptimal blood pressure (BP) control has 
been well documented in the majority of studies assessing BP control in diabetic patients in 
sub-Saharan Africa. In Uganda, there is a dearth of similar studies. This study evaluated the 
prevalence and correlates of suboptimal BP control in an adult diabetic population in Uganda.
Patients and methods: This was a cross-sectional study that enrolled 425 eligible ambulatory 
adult diabetic patients attending three urban diabetic outpatient clinics over 11 months. Data 
about their sociodemographic characteristics and clinical history were collected using pre-tested 
questionnaires. Suboptimal BP control was defined according to the 2015 American Diabetes 
Association standards of diabetes care guideline as BP levels $140/90 mmHg.
Results: The mean age of the study participants was 52.2±14.4 years, with the majority 
being females (283, 66.9%). Suboptimal BP control was documented in 192 (45.3%) study 
participants and was independently associated with the study site (private hospitals; odds ratio 
2.01, 95% confidence interval 1.18–3.43, P=0.01) and use of statin therapy (odds ratio 0.5, 95% 
confidence interval 0.26–0.96, P=0.037).
Conclusion: Suboptimal BP control was highly prevalent in this study population. Strategies 
to improve optimal BP control, especially in the private hospitals, and the use of statin therapy 
should be encouraged in adult diabetic patients.
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Introduction
Globally, cardiovascular diseases (CVDs) are the leading causes of adult morbidity and 
mortality. In 2012, an estimated 17.5 million people died from CVDs, which represents 
31% of all global deaths. Approximately 80% of these deaths are documented to occur 
in low- and middle-income countries.1 Hypertension (HT) is one of the documented 
traditional risk factors of CVDs.2 Diabetes mellitus (DM)–HT comorbidity is frequently 
encountered in clinical practice, especially among adult diabetic patients.3,4 Optimal 
control of both conditions is associated with delayed onset and progression of micro-
vascular and macrovascular complications and related cardiovascular mortality.5,6 
Despite several studies reporting the burden and predictors of suboptimal blood 
pressure (BP) control among African diabetic patients, similar studies are limited 
in Uganda.4,7 Hence, this study sought to examine the prevalence and correlates of 
suboptimal BP control in an adult diabetic population attending three urban outpatient 
diabetic clinics in Uganda.
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Patients and methods
This was a cross-sectional study performed from September 
2014 to July 2015 at three urban outpatient diabetic clin-
ics of Mulago National Referral and Teaching Hospital, a 
public hospital where health care services are offered at no 
charge, and at Mengo Hospital and Our lady of Consolata 
Hospital, Kisubi, which are not-for-profit faith-based hos-
pitals where health services are offered to patients at lower 
costs. These three hospitals serve an urban population of ~2 
million people.
The diabetes clinic is usually run once weekly in the 
morning for enrollment of new patients and follow-up 
of old registered patients. An average of 35 patients are 
reviewed on each clinic day by either a general practitioner 
or a specialist physician. At each visit, patients are offered 
diabetic education by an experienced diabetic educator or 
nurse that includes information about diabetes, its complica-
tions such as HT, nutrition, adherence to medications and 
self-monitoring. BP measurement is usually performed using 
either a digital BP machine or a mercury sphygmomanometer 
by a diabetes nurse after at least 15 minutes of rest. Anthro-
pometric measurements of height and weight to calculate 
the body mass index (BMI) and measurement of the fasting 
blood sugar level using an early morning fasting capillary 
blood sample are also routinely done at each visit.
At each center, patients aged $18 years with a confirmed 
diagnosis of diabetes by a general practitioner or a physician 
using fasting blood glucose levels, an oral glucose tolerance 
test, glycated hemoglobin (HbA1c) or random blood sugar 
level in the presence of symptoms of diabetes; patients who 
had been receiving care for at least a minimum of 6 months 
and patients who provided written informed consent were 
considered eligible and enrolled consecutively until the 
desired sample size was attained. Patients who were too sick 
to provide written informed consent were excluded from the 
study (Figure 1).
Data collection
Using a pre-tested questionnaire, information about the 
study participants’ sociodemographic characteristics, pre-
existing medical conditions (coexisting HT and HIV), type 
of diabetes, age at diagnosis of DM, duration since diagnosis 
and drug history was collected.
After providing written informed consent, all study par-
ticipants were subjected to a single BP measurement using 
a digital BP machine following a minimum of 15 minutes 
rest at the clinic. They also underwent standard weight and 
height measurements to calculate the BMI and measurement 
of HbA1c, low-density lipoprotein cholesterol (LDLC), high-
density lipoprotein cholesterol (HDLC), triglyceride and 
total cholesterol (TC) concentrations using a fasting venous 
blood. The analysis of the above blood tests was done at 
each center using a fully automated COBAS® INTEGRA 400 
(Hoffman-La Roche Ltd., Basel, Switzerland) machine.
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Figure 1 Flow chart of enrollment of study participants.
Abbreviation: DM, diabetes mellitus.
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statistical analysis
Data were entered into Microsoft Excel database, and Stata 
software (version 12.1) was used for all statistical analyses. 
Patient characteristics were reported as frequencies and 
percentages for categorical variables and median and inter-
quartile range (IQR) values for continuous variables, which 
were not normally distributed.
The 2015 American Diabetes Association guideline 
of standards of diabetes care was used to define subop-
timal BP control among adult diabetic patients as BP 
levels $140/90 mmHg, regardless of the patient category, 
ie, age, duration of disease or presence of concomitant 
comorbidities.8 We also defined normal or optimal BP and 
stage 1 and stage 2 HT as BP ,140/90 mmHg, BP =140–
159/90–99 mmHg and BP $160/100 mmHg, respectively.
To determine the associations between the different 
sociodemographic, clinical and laboratory factors and sub-
optimal BP control, bivariate analyses using chi-square test 
were performed. Multivariate analysis was performed using 
logistic regression to identify the independent predictors of 
suboptimal BP control. The model was built in a stepwise 
manner by initially putting all variables with P-values ,0.2 
in the bivariate analysis and reducing the model starting with 
those that did not lower the Akaike information criterion. 
Variables that were biologically plausible were also included 
in the final model. A P-value of ,0.05 and confidence inter-
vals (CIs) not including 1 were considered to be statistically 
significant.
ethics approval
This study was approved by the ethical review boards of 
Makerere University College of Health Sciences, Mengo 
Hospital and Our Lady of Consolata Hospital, Kisubi.
Results
sociodemographic and clinical 
characteristics of the study participants
The median (IQR) age of the study participants was 53 years 
(43.5–62 years). The majority of the participants were 
females (284, 66.98%) and had primary or lower level of 
education (165, 38.92%). Family history of DM and HT 
comorbidity was documented in 62.26% and 68.87% of 
the study participants, respectively. All patients with coex-
isting HT were on BP-lowering treatment with either an 
angiotensin-converting enzyme inhibitor or angiotensin II 
receptor blocker component. Insulin therapy, oral glucose-
lowering agents and statin therapy were used in 44.34%, 
55.7% and 20.94% of the study participants, respectively 
(summarized in Table 1).
Table 1 sociodemographic, clinical and laboratory characteristics 
of the study participants
Variable Values
age (years), median (iQR) 53 (43.5–62)
gender, n (%)
Male 140 (33.02)
Female 284 (66.98)
education level, n (%)
none 38 (8.96)
Primary 165 (38.92)
secondary 141 (33.25)
Tertiary 79 (18.63)
Occupation, n (%)
employed 212 (50)
Unemployed 212 (50)
Marital status, n (%)
Married 259 (61.08)
Cohabiting 10 (2.36)
single 47 (11.08)
Divorced 41 (9.67)
Widow/widowed 67 (15.80)
Place of residence, n (%)
Rural 136 (32.08)
Urban 288 (67.92)
study site, n (%)
government 199 (46.82)
Private 226 (53.18)
smoking, n (%)
Yes 10 (2.35)
no 415 (97.65)
Known hT, n (%)
Yes 292 (68.87)
no 132 (31.13)
hiV coexistent, n (%)
Yes 17 (4.00)
no 408 (96.00)
Family history of DM, n (%)
Yes 264 (62.26)
no 160 (37.74)
Type of DM, n (%)
Type 1 DM 55 (13.13)
Type 2 DM 364 (86.87)
Drug history, n (%)
Diet alone 3 (0.71)
Met alone 79 (18.59)
Met + sU 127 (29.88)
Met + sU + TZD 16 (3.76)
Met + incretin 8 (1.88)
insulin alone/+ Met 188 (44.34)
statins 89 (20.94)
Median (IQR), N=425
age at diagnosis (years) 47 (37–55)
Duration with DM (years) 4.5 (2–10)
BMi (kg/m2) 27 (23–30.6)
hba1c (%) 9 (6.8–12.4)
lDlC (mmol/l) 2.9 (2.3–3.84)
hDlC (mmol/l) 1.19 (0.9–1.42)
TC (mmol/l) 4.82 (4.1–5.71)
Tgl (mmol/l) 1.6 (1.23–2.2)
sBP (mmhg) 139 (124–155)
DBP (mmhg) 80 (73–91)
Note: Copyright ©2017. Dove Medical Press. Reproduced from Kibirige D, akabwai 
gP, Kampiire l, Kiggundu Ds, lumu W. Frequency and predictors of suboptimal 
glycemic control in an african diabetic population. Int J Gen Med. in press 2017.17
Abbreviations: iQR, interquartile range; hT, hypertension; DM, diabetes mellitus; 
Met, metformin; sU, sulfonylurea; BMi, body mass index; hba1c, glycated hemo­
globin; lDlC, low­density lipoprotein cholesterol; hDlC, high­density lipoprotein 
cholesterol; TC, total cholesterol; Tgl, triglyceride; TZD, thiazolidinedione; sBP, 
systolic blood pressure; DBP, diastolic blood pressure.
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status of BP control
The median systolic BP (SBP) and diastolic BP (DBP) were 
139 mmHg (124–155 mmHg) and 80 mmHg (73–91 mmHg), 
respectively. Suboptimal BP control was noted in 192 study 
participants, giving a prevalence of 45.3%. Of these par-
ticipants with suboptimal BP control, 91 (21.41%) and 101 
(23.76%) had stage 1 and stage 2 HT, respectively. None of 
the participants with DM–HT comorbidity had optimal BP 
control of ,140/90 mmHg.
sociodemographic, clinical and laboratory 
characteristics of the study participants 
at bivariate analysis
At bivariate analysis, age in completed years (P=0.019), 
gender (P=0.032), study site (P=0.007), type of diabetes 
(P=0.164), median age at diagnosis (P=0.025), median years 
with diabetes (P=0.126), BMI (P=0.040), metformin (Met) 
and sulfonylurea (SU; P=0.071), incretin and Met combina-
tion (P=0.097), Met, SU and thiazolidinedione (TZD) com-
bination (P=0.167), insulin therapy (P=0.073), statin therapy 
(P=0.081), LDLC levels (P=0.077), HDLC levels (P=0.108), 
TC levels (P=0.042) and non-HDLC (P=0.071) were consid-
ered. Table 2 summarizes the sociodemographic, clinical and 
laboratory characteristics of the study participants in associa-
tion with suboptimal BP control at bivariate analysis.
independent predictors of suboptimal BP 
control at multivariate analysis
At multivariate analysis, the only independent predictors of 
suboptimal BP control were type of study site (private hos-
pitals; adjusted odds ratio 2.01, 95% CI 1.18–3.43, P=0.010) 
and use of statin therapy (adjusted odds ratio 0.50, 95% 
CI 0.26–0.96, P=0.037; shown in Table 3).
Discussion
This cross-sectional study demonstrates a high prevalence 
of suboptimal BP control in this study population, account-
ing for ~5 in 10 adult diabetic patients. Patients seeking 
diabetes care from a private hospital were twice more likely 
to have suboptimal BP control compared to those attending 
the government hospital. The use of statin therapy reduced 
the likelihood of suboptimal BP control by 50%.
High prevalence of suboptimal BP control has been 
reported in African diabetic patients in several studies.4,7,9–11 
In the largest study to assess the quality of diabetes care 
performed among adult diabetic patients in sub-Saharan 
Africa to date, the Diabcare Africa study, suboptimal 
BP control was documented in 79% of the 2,352 study 
participants.4 Other similar smaller studies conducted in 
Uganda, Ethiopia and South Africa have reported prevalence 
between 44% and 68%.7,9–11
In comparison to our study, the wide disparity in the 
documented prevalence could be explained by varying 
study definitions of suboptimal BP control. Most of the 
above studies defined suboptimal BP control as BP .130/ 
80 mmHg, BP $140/80 mmHg or SBP $130 mmHg and/
DBP $80 mmHg.
independent predictors of suboptimal 
BP control
Seeking diabetes care from private hospitals and use of statin 
therapy were independently associated with suboptimal BP 
control. The probable reason to explain the increased likeli-
hood of suboptimal BP control among patients receiving 
diabetes care from private hospitals is the high cost of 
antihypertensive drugs. This directly affects access to these 
drugs and adherence, resulting into suboptimal BP control. 
In Uganda, medical care in government hospitals is offered 
at no cost to the patients. Patients attending diabetes clinics 
in these hospitals are offered the prescribed antihypertensive 
drugs and glucose-lowering drugs free of charge if available 
in the hospital pharmacies.
The use of statin therapy reduced the likelihood of 
suboptimal BP control in this study population. To our 
knowledge, this correlation has not been demonstrated in 
any study in African diabetic patients. Some studies have 
shown that statins offer modest BP reductions, a clinical 
benefit that is independent of their recognized lipid-lowering 
properties. In one large cross-sectional study performed 
using data from the national health and nutritional survey 
in the USA, the effect of statins on BP was evaluated in 
995 patients on statin treatment and 9,536 patients not on 
statins.12 They were stratified according to the history of 
use of antihypertensive drugs, BP and HDLC levels. Statin 
therapy decreased SBP by 3.3 mmHg among patients on 
antihypertensive medication (interaction P,0.02); reduced 
DBP by an average of 1.9 mmHg (P,0.01), regardless of 
antihypertensive medication use, and in patients with low 
HDLC (#49 mmHg), reduced DBP by 3.4 mmHg. Among 
patients on antihypertensive medications, statin users had a 
lower mean SBP of 4 mmHg compared to the statin nonusers. 
This study concluded that statin therapy contributes to 
optimal BP control in hypertensive patients and in patients 
with low HDLC levels. In our study, 68.9% and 29.2% of 
the study participants had HT comorbidity and low HDLC 
levels (defined as levels ,40 mg/dL).
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Table 2 Bivariate analysis of sociodemographic and clinical characteristics associated with suboptimal BP control
Characteristics BP $140/90 mmHg BP ,140/90 mmHg OR (95% CI) P-value
age (years), mean (sD) 53.98 (0.99) 50.67 (0.97) 1.02 (1.00–1.03) 0.019
gender, n (%)
Male 139 (72.40) 87 (37.50) 1
Female 53 (27.60) 145 (62.50) 0.64 (0.420–0.961) 0.032
Type of hospital, n (%)
government 88 (45.83) 137 (59.05) 1
Private 104 (54.17) 95 (40.95) 1.70 (1.158–2.507) 0.007
Place of residence, n (%)
Rural 125 (65.10) 163 (70.26) 1
Urban 67 (34.90) 69 (29.74) 1.27 (0.841–1.906) 0.258
smoking, n (%)
smoker 3 (1.56) 7 (3.02) 1
non­smoker 189 (98.44) 225 (96.98) 0.51 (0.130–2.000) 0.334
Occupation, n (%)
employed 92 (47.92) 120 (51.72) 1
Unemployed 100 (52.08) 112 (48.28) 0.86 (0.586–1.26) 0.435
DM type, n (%)
Type 2 DM 169 (89.42) 195 (84.78) 1
Type 1 DM 20 (10.58) 35 (15.22) 0.66 (0.367–1.186) 0.164
Family history of DM, n (%)
Yes 121 (63.02) 143 (61.64) 1
no 71 (36.98) 89 (38.36) 1.06 (0.715–1.574) 0.770
hiV comorbidity, n (%)
Yes 8 (4.17) 9 (3.88) 1
no 184 (95.83) 223 (96.12) 1.08 (0.407–2.848) 0.881
Median age (years) at diagnosis, n (%) 47.49 (12.74) 44.60 (13.39) 1.02 (1.00–1.03) 0.025
Median years with DM, n (%) 7.34 (6.53) 6.40 (6.07) 1.02 (0.99–1.06) 0.126
BMi (kg/m2), n (%) 28.03 (5.98) 26.76 (6.28) 1.03 (1.00–1.07) 0.040
glucose lowering therapy, n (%)
Met alone 38 (48.10) 41 (51.90) 1.15 (0.704–1.876) 0.577
Met + sU 66 (51.97) 61 (48.03) 1.47 (0.967–2.229) 0.071
incretin** + Met 1 (12.50) 7 (87.50) 0.17 (0.205–1.380) 0.097
Met + sU + TZD 10 (62.50) 6 (37.50) 2.07 (0.738–5.802) 0.167
insulin alone/+ Met 76 (40.43) 112 (59.72) 0.70 (0.477–1.034) 0.073
On statin therapy, n (%)
no 159 (47.46) 176 (52.54) 1
Yes 33 (37.08) 56 (62.92) 1.53 (0.95–2.48) 0.081
lDlC, median (iQR) 2.97 (2.4–3.86) 2.88 (2.22–3.8) 1.16 (0.98–1.37) 0.077
hDlC, median (iQR) 1.2 (0.96–1.5) 1.16 (0.9–1.4) 1.43 (0.92–2.22) 0.108
TC, median (iQR) 5 (4.24–5.89) 4.74 (4–5.65) 1.17 (1.00–1.36) 0.042
Tgl, median (iQR) 1.66 (1.28–2.15) 1.54 (1.19–2.24) 0.96 (0.79–1.15) 0.632
non­hDlC, median (iQR) 3.59 (2.8–4.5) 3.67 (3.02–4.69) 1.16 (0.99–1.37) 0.071
TC/hDlC ratio, median (iQR) 4.14 (3.3–5.4) 4.2 (3.3–5.2) 0.98 (0.90–1.07) 0.717
Note: **all the patients were on a saxagliptin.
Abbreviations: BP, blood pressure; OR, odds ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; Met, metformin; SU, sulfonylurea; TZD, thiazolidione; 
lDlC, low­density lipoprotein cholesterol; iQR, interquartile range; hDlC, high­density lipoprotein cholesterol; TC, total cholesterol; Tgl, triglyceride.
The effect of BP lowering due to statin therapy was 
also demonstrated in the University of California, San 
Diego Statin Study. This was a randomized, double-blind, 
placebo-controlled trial in which 973 men and women 
without known CVD or DM were equally randomized 
to simvastatin 20 mg, pravastatin sodium 40 mg and 
placebo for 6 months.13 The study demonstrated that 
statins modestly but significantly reduced BP relative to 
placebo, by 2.2 mmHg for SBP (P=0.02) and 2.4 mmHg 
for DBP (P,0.001).
This statin-related BP-lowering effect and other additional 
beneficial effects that are independent of the lipid-lowering 
properties are called pleiotropic effects. Experimental observa-
tions have shown that statins have cellular anti-inflammatory, 
anti-proliferative and immunomodulatory effects, cause 
plaque stabilization, prevent platelet aggregation through 
Therapeutics and Clinical Risk Management 2017:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
220
lumu et al
their inhibition effect on thromboxane A2, improve endothe-
lial nitric oxide (NO) bioavailability and reduce cellular 
oxidative stress.14–16
The pleiotropic effect of BP lowering by statins is explained 
by several mechanisms. Statins induce increased expression 
of endothelial NO synthase, which increases bioavailability 
of NO, a potent vasodilator and inhibitor of vascular thrombo-
sis and inflammation. Statins also have demonstrated cellular 
anti-oxidative properties, which limit vascular damage. This 
is because of their effect of preventing isoprenylation of the 
GTP-binding protein p21 Rac, which reduces production of 
nicotinamide adenine dinucleotide phosphate oxidase and 
reactive oxygen species in endothelial cells, which would 
scavenge the vasodilating NO. Statins also induce increased 
production of thrombomodulin and tissue plasminogen 
activator and inhibit vascular smooth muscle cell prolifera-
tion, expression of vascular cell adhesion molecules such 
as VCAM-1 and sICAM-1, expression of angiotensin I 
receptor and angiotensin II-dependent intracellular signaling 
and synthesis of angiotensin II and aldosterone.14–16 These 
multiple effects are integral in maintaining normal vasomotor 
tone and hemostatic balance.
study limitations
Because of the nature of the study (cross-sectional study 
performed in three urban hospitals), we cannot generalize 
to the entire adult diabetic population seeking care in 
Uganda. A single BP reading was used, which might affect 
the results obtained. Despite these limitations, this is the 
first large multicenter study to examine the prevalence of 
suboptimal BP control and its predictors in adult diabetic 
patients in Uganda.
Conclusion and recommendations
Suboptimal BP control was relatively common in this study 
population. Approaches to improve BP control should be 
emphasized among diabetic patients seeking care from 
private hospitals. Routine use of statins should be encouraged 
in patients with DM–HT comorbidity to maintain optimal 
BP control. In-depth qualitative studies to identify causes of 
suboptimal BP control in adult diabetic patients should be 
undertaken to assist in offering practical solutions and guide 
policy formulation and implementation.
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age at 
diagnosis, years
1.02 (1.00–1.03) 0.025 1.01 (0.98–1.04) 0.586
Met and sU 1.47 (0.97–2.23) 0.071 1.36 (0.80–2.29) 0.254
Met–sU–TZD 2.07 (0.74–5.80) 0.167 2.59 (0.73–9.17) 0.139
On statin 
therapy
1.53 (0.95–2.48) 0.081 0.50 (0.26–0.96) 0.037
Abbreviations: BP, blood pressure; OR, odds ratio; CI, confidence interval; BMI, 
body mass index; DM, diabetes mellitus; lDlC, low­density lipoprotein cholesterol; 
Met, metformin; sU, sulfonylurea; TZD, thiazolidione.
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